Exon 19 deletion and exon 21 L858R point mutation are regarded as two separate entities, resulting in different structural changes in EGFR, differences in the rate of concomitant mutations, and differences in the overall tumor mutation burden [24]. The gene discussed is EGFR; the disease is neoplasm.